Lung Neoplasm Malignant: Clinical Trials

2 recruiting. 2 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	2	Recruiting 2
Phase 1	1	Recruiting 1

Follow Lung Neoplasm Malignant: new trials by email Literature Review of Lung Neoplasm Malignant trials Research Report on Lung Neoplasm Malignant

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan - Lung Neoplasm Malignant	Phase 1 / Phase 2	Recruiting	Merck Sharp & Dohme LLC	140	2026-04-30	2026-10-01
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors Low-dose radiotherapy to the intestine (ILDR), PD-1/PD-L1 monoclonal antibodies - Radiotherapy, Metastatic Solid Cancers	Phase 2	Recruiting	Chuangzhen Chen	48	2025-09-26	2025-11-20

Narrower conditions

Lung Neoplasms (2)  ·  Esophageal Neoplasms (1)

Broader conditions

Lung Diseases (2)  ·  Neoplasms (2)  ·  Neoplasms by Site (2)  ·  Respiratory Tract Diseases (2)  ·  Respiratory Tract Neoplasms (2)  ·  Thoracic Neoplasms (2)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Esophageal Diseases (1)  ·  Gastrointestinal Diseases (1)  ·  Gastrointestinal Neoplasms (1)  ·  Head and Neck Neoplasms (1)

Interventions

Cetuximab (1)  ·  patritumab deruxtecan (1)

Sponsors

Chuangzhen Chen (1)  ·  Merck Sharp & Dohme LLC (1)

Countries

China (2)  ·  Brazil (1)  ·  Chile (1)  ·  Germany (1)  ·  Greece (1)  ·  Hong Kong (1)  ·  Israel (1)  ·  Italy (1)  ·  South Korea (1)  ·  Spain (1)  ·  United States (1)